InsiderPulse
Dashboard

GILD

Gilead Sciences, Inc.

Health CareS&P 500NASDAQ 100

Gilead Sciences, Inc. insider trading

Gilead Sciences, Inc. files with the SEC as a Biological Products, (No Diagnostic Substances) company headquartered in Foster City, CA. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

From SEC filings

Recent GILD insider transactions

5 insiders traded GILD on the open market between Jul 15, 2026 and Sep 15, 2026 — 24 sales worth $13.5M, of which every one was pre-scheduled under a 10b5-1 plan.

Bought
—
Sold
$13.5M

24 of 24 on a 10b5-1 plan

Net
−$13.5M
Insiders
5

Open-market purchases (code P) and sales (code S) from Gilead Sciences, Inc.'s own SEC Form 4 filings. Grants and option exercises are excluded — they are compensation, not decisions. Share counts are derived from the reported value and price. Verify any figure against the original filing before acting on it; this is monitoring, not advice.

Filing history last read from EDGAR on Sep 21, 2026. The live dashboard shows new filings the moment they clear.

Every GILD Form 4 on SEC.gov

SEC Form 4 data, Q3 2024 to Q2 2026

GILD insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 7 insiders traded GILD on the open market: 0 purchases and 103 sales worth $162.5M, 101 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 0 purchases and 67 sales ($78.7M), by 6 insiders.

QuarterBoughtSold
Q2 2026—−$8.9M16 sales · all on a plan
Q1 2026—−$44.2M17 sales · all on a plan
Q4 2025—−$16.9M18 sales · 17 on a plan
Q3 2025—−$8.7M16 sales · all on a plan
Q2 2025—−$5M10 sales · all on a plan
Q1 2025—−$30.8M7 sales · all on a plan
Q4 2024—−$42.5M13 sales · 12 on a plan
Q3 2024—−$5.5M6 sales · all on a plan
Largest sale
−$17.3M of GILD by O'Day Daniel Patrick (Chairman & CEO · Director) on Feb 05, 2026, under a 10b5-1 plan.

Open-market transactions through Jun 30, 2026most recent first

  • Dickinson Andrew D10b5-1

    Chief Financial Officer

    −$376.2K

    Jun 15, 2026

    3,000 sh · $125.40

  • Mercier Johanna10b5-1

    Chief Comm & Corp Aff Officer

    −$182.7K

    Jun 15, 2026

    1,480 sh · $123.42

  • Mercier Johanna10b5-1

    Chief Comm & Corp Aff Officer

    −$132.7K

    Jun 15, 2026

    1,070 sh · $124.00

  • Mercier Johanna10b5-1

    Chief Comm & Corp Aff Officer

    −$56.4K

    Jun 15, 2026

    450 sh · $125.40

  • O'Day Daniel Patrick10b5-1

    Chairman & CEO · Director

    −$1.4M

    Jun 01, 2026

    10,900 sh · $131.10

  • O'Day Daniel Patrick10b5-1

    Chairman & CEO · Director

    −$404.9K

    Jun 01, 2026

    3,062 sh · $132.22

  • O'Day Daniel Patrick10b5-1

    Chairman & CEO · Director

    −$138K

    Jun 01, 2026

    1,038 sh · $132.97

  • Mercier Johanna10b5-1

    Chief Comm & Corp Aff Officer

    −$1.5M

    May 15, 2026

    11,177 sh · $131.19

  • Mercier Johanna10b5-1

    Chief Comm & Corp Aff Officer

    −$1.1M

    May 15, 2026

    8,374 sh · $132.23

  • Mercier Johanna10b5-1

    Chief Comm & Corp Aff Officer

    −$1M

    May 15, 2026

    7,749 sh · $130.29

  • Dickinson Andrew D10b5-1

    Chief Financial Officer

    −$396.8K

    May 15, 2026

    3,000 sh · $132.27

  • Mercier Johanna10b5-1

    Chief Comm & Corp Aff Officer

    −$92.9K

    May 15, 2026

    700 sh · $132.75

  • O'Day Daniel Patrick10b5-1

    Chairman & CEO · Director

    −$895.1K

    Apr 28, 2026

    6,950 sh · $128.79

  • O'Day Daniel Patrick10b5-1

    Chairman & CEO · Director

    −$396.5K

    Apr 28, 2026

    3,050 sh · $130.01

  • Dickinson Andrew D10b5-1

    Chief Financial Officer

    −$422.9K

    Apr 15, 2026

    3,000 sh · $140.96

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

Gilead Sciences, Inc. company record

SEC industry classification
Biological Products, (No Diagnostic Substances)
Headquarters
Foster City, CA
Incorporated in
DE
Listed on
Nasdaq
SEC Central Index Key
0000882095

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

After insiders bought GILD

What the stock actually did in the 90 days following each open-market purchase

Don't check GILD — let it ping you

Get told the moment an insider moves on GILD

Pro watches Gilead Sciences, Inc. for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add GILD to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track GILD on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read GILD insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

VRTXREGNISRGSYKBSXMDTCICVSELVHCAZTSMRNA
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

Are GILD insiders buying or selling?
Between Jul 15, 2026 and Sep 15, 2026, 5 Gilead Sciences, Inc. insiders made no open-market purchases and 24 sales worth $13.5M, a net sale of $13.5M. 24 of the sales were pre-scheduled under a Rule 10b5-1 plan.
How much GILD stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 7 Gilead Sciences, Inc. insiders made no open-market purchases and 103 sales worth $162.5M. 101 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and 67 sales ($78.7M). The largest sale was O'Day Daniel Patrick selling $17.3M on Feb 05, 2026.
What was the largest recent GILD insider trade?
Mercier Johanna (Chief Comm & Corp Aff Officer) sold $2.3M of GILD stock on Aug 17, 2026 at about $137.37 a share, under a pre-scheduled 10b5-1 plan.
When did an insider last buy GILD shares?
No open-market purchase by a Gilead Sciences, Inc. insider appears in the filings from Jul 15, 2026 to Sep 15, 2026 — every recorded open-market transaction in that period was a sale.
Where does GILD insider trading data come from?
From the Form 4 filings Gilead Sciences, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.